HM2017-24 : Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM-027

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- age 18 or older - able to walk and do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - confirmed diagnosis of classical Hodgkin lymphoma that has reoccurred or not responded to treatment - women and men who are of child bearing age must use required birth control - there are additional criteria for prior treatment and laboratory results (study staff will review)

Exclusion Criteria:

- inability to swallow oral medication or any condition that affects absorption of oral medications - women who are pregnant or breast feeding - additional criteria about current medical history (study staff will review)

Conditions & Interventions

Interventions:
Drug: Nivolumab, Drug: Ruxolitinib
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Hodgkin Lymphoma

More Information

Description: Participants who take part in this study will receive a study drug called ruxolitinib with a standard drug called nivolumab. The study is being done to measure the percentage of tumor (lymphoma) that shrinks after receiving ruxolitinib in combination with nivolumab. This study will also measure the length of time the lymphoma is inactive and how safe the combination is to administer to participants. Ruxolitinib is a pill that is taken twice every day. Nivolumab is given as an infusion in the clinic once every 4 weeks.
Study Contact: Veronika Bachanova - bach0173@umn.edu
Principal Investigator: Veronika Bachanova, MD
Phase: PHASE1
IRB Number: STUDY00001341